RN Mobile Menu

Search form



Will You Buy In on the Next Biosimilar?

The FDA has deferred a scheduled meeting about Remsima, the infliximab biosimilar already approved in Europe and still awaiting judgment in the US. But approval of the first US biosimilar (a version of the cancer drug filgrastim) prompted warnings from two organizations concerned with rheumatic disease, including the ACR. Are you ready the next challenge to your clinical judgment?



A new study finds that low doses of fish oil improved pain and function in knee osteoarthritis more effectively than high doses. No clinical or structural advantage to an anti-inflammatory dose was found.


Developing arthritis increases the risk of falling into poverty, especially for women, a new study shows.


The use of steroid injections for low back pain is increasing, even though the evidence supporting it is declining.

Patients with tophaceous gout rarely develop ulcers, but when they do occur, these ulcers can be difficult to treat. This case study explores the diagnosis of and treatment options for patients with ulcerated tophaceous gout.

Intravenous Medications

Clinical trial of 120 RA patients shows that adalimumab (Exemptia) works as well as adalimumab (Humira).

The majority of pregnant patients with systemic lupus erythematosus (SLE) have favorable pregnancy outcomes, with few experiencing severe flares.

Patients diagnosed with systemic sclerosis (SSc) may have a three times greater risk of venous thromboembolism (VTE) – including potentially deadly clots in the lungs – and an increased risk in the first year after a diagnosis.


Subscribe to Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.